Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: A double-blind placebo and bupropion-controlled study

Schizophrenia Research

Volumn 146, Issue 1-3, 2013, Pages 376-378

  Fatemi, S Hossein ^a   Yousefi, Mahtab K ^a   Kneeland, Rachel E ^a   Liesch, Stephanie B ^a   Folsom, Timothy D ^a   Thuras, Paul D ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; COTININE; PLACEBO; VARENICLINE;

ANTIPSYCHOTIC EFFECT; ANTISMOKING EFFECT; BLOOD LEVEL; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; COTININE BLOOD LEVEL; COTININE URINE LEVEL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TOBACCO DEPENDENCE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINE LEVEL;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BENZAZEPINES; BUPROPION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NICOTINIC AGONISTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUINOXALINES; SCHIZOPHRENIA; SMOKING;

EID: 84875936380     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.02.015     Document Type: Letter

References (11)

1. Beary M., Hodgson R., Wildgust H.J. A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications. J. Psychopharmacol. 2012, 26(5 Suppl.):52-61.
2. Bozikas V.P., Papakosta M., Niopas I., Karavatos A., Mirtsou-Fidani V. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. Eur. Neuropsychopharmacol. 2004, 14(1):39-44.
3. Cerimele J.M., Durango A. Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies. J. Clin. Psychiatry 2012, 73(8):e1039-1047.
4. Evins A.E., Goff D.C. Varenicline treatment for smokers with schizophrenia: a case series. J. Clin. Psychiatry 2008, 69(6):1016.
5. Fatemi S.H. Varenicline efficacy and tolerability in a subject with schizophrenia. Schizophr. Res. 2008, 103(1-3):328-329.
6. Nino-Gomez J., Carlini S., Nemani K., Cather C., Pratt S., Evins A.E. Safety and efficacy of varenicline in schizophrenia: preliminary data from 12-week trial. Abstract Presented at the 16th Annual Meeting of the Society for Research on Nicotine and Tobacco; Feb 24-Feb 27, 2010; Baltimore, MD 2010.
7. Ortiz N.C., O'Neill H.C., Marks M.J., Grady S.R. Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo. Nicotine Tob. Res. 2012, 14(6):711-719.
8. Pachas G.N., Cather C., Pratt S.A., Hoeppner B., Nino J., Carlini S.V., Achtyes E.D., Lando H., Mueser K.T., Rigotti N.A., Goff D.C., Evins A.E. Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week, open-label trial. J. Dual Diagn. 2012, 8(2):117-125.
9. Smith R.C., Lindenmayer J.P., Davis J.M., Cornwell J., Noth K., Gupta S., Sershen H., Lajtha A. Cognitive and antismoking effects of varenicline in patients with schizophrenia and schizoaffective disorder. Schizophr. Res. 2009, 110(1-3):149-155.
10. Weiner E., Buchholz A., Coffay A., Liu F., McMahon R.P., Buchanan R.W., Kelly D.L. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr. Res. 2011, 129(1):94-95.
11. Williams J.M., Anthenelli R.M., Morris C.D., Treadow J., Thompson J.R., Yunis C., George T.P. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 2012, 73(5):654-660.